Literature DB >> 25727225

An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas.

Sam Q Sun1, Ammar H Hawasli, Jiayi Huang, Michael R Chicoine, Albert H Kim.   

Abstract

The management of WHO Grade II "atypical" meningiomas (AMs) and Grade III "malignant" meningiomas (MMs) remains controversial and under-investigated in prospective studies. The roles of surgery, radiation therapy, radiosurgery, and chemotherapy have been incompletely delineated. This has left physicians to decipher how they should treat patients on a case-by-case basis. In this study, the authors review the English-language literature on the management and clinical outcomes associated with AMs and MMs diagnosed using the WHO 2000/2007 grading criteria. Twenty-two studies for AMs and 7 studies for MMs were examined in detail. The authors examined clinical decision points using the literature and concepts from evidence-based medicine. Acknowledging the retrospective nature of the studies concerning AM and MM, the authors did find evidence for the following clinical strategies: 1) maximal safe resection of AM and MM; 2) active surveillance after gross-total resection of AM; 3) adjuvant radiation therapy after subtotal resection of AM, especially in the absence of putative radioresistant features; and 4) adjuvant radiation therapy after resection of MM.

Entities:  

Keywords:  AM = Grade II meningioma (atypical meningioma); EBM = evidence-based medicine; EBRT = external beam radiation therapy; EGFR = epidermal growth factor receptor; EOR = extent of resection; GTR = gross-total resection; LC = local control; MM = Grade III meningioma (malignant meningioma); NTR = near-total resection; OS = overall survival; PDGFR = platelet-derived growth factor receptor; PFS = progression-free survival; RTK = receptor tyrosine kinase; SRS = stereotactic radiosurgery; STR = subtotal resection; VGFR = vascular endothelial growth factor receptor; anaplastic meningioma; atypical meningioma; malignant meningioma; meningioma

Mesh:

Year:  2015        PMID: 25727225     DOI: 10.3171/2015.1.FOCUS14757

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  33 in total

1.  Boron Neutron Capture Therapy for High-Grade Skull-Base Meningioma.

Authors:  Koji Takeuchi; Shinji Kawabata; Ryo Hiramatsu; Yoko Matsushita; Hiroki Tanaka; Yoshinori Sakurai; Minoru Suzuki; Koji Ono; Shin-Ichi Miyatake; Toshihiko Kuroiwa
Journal:  J Neurol Surg B Skull Base       Date:  2018-07-03

2.  Early or late radiotherapy following gross or subtotal resection for atypical meningiomas: Clinical outcomes and local control.

Authors:  Ammoren Dohm; Emory R McTyre; Michael D Chan; Claire Fan; Scott Isom; J Daniel Bourland; Ryan T Mott; Christina K Cramer; Stephen B Tatter; Adrian W Laxton
Journal:  J Clin Neurosci       Date:  2017-09-13       Impact factor: 1.961

3.  Primary management of atypical meningioma: treatment patterns and survival outcomes by patient age.

Authors:  Ernest Barthélemy; Joshua Loewenstern; Neeraja Konuthula; Margaret Pain; Jordan Hall; Satish Govindaraj; Joshua Bederson; Raj K Shrivastava
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-02       Impact factor: 4.553

4.  Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution.

Authors:  Suresh K Balasubramanian; Mayur Sharma; Danilo Silva; Vidhya Karivedu; Philipp Schmitt; Glen H Stevens; Gene H Barnett; Richard A Prayson; Paul Elson; John H Suh; Erin S Murphy; Samuel T Chao
Journal:  J Neurooncol       Date:  2016-11-18       Impact factor: 4.130

5.  De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Authors:  Matthieu Peyre; Guillaume Gauchotte; Marine Giry; Sébastien Froehlich; Johan Pallud; Thomas Graillon; Franck Bielle; Dominique Cazals-Hatem; Pascale Varlet; Dominique Figarella-Branger; Hugues Loiseau; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

6.  Racial and socioeconomic correlates of treatment and survival among patients with meningioma: a population-based study.

Authors:  Hriday P Bhambhvani; Adrian J Rodrigues; Zachary A Medress; Melanie Hayden Gephart
Journal:  J Neurooncol       Date:  2020-03-19       Impact factor: 4.130

7.  Microsurgical management of primary jugular foramen meningiomas: a series of 22 cases and review of the literature.

Authors:  Jie Tang; Liwei Zhang; Junting Zhang; Zhen Wu; Xinru Xiao; Dabiao Zhou; Guijun Jia; Wang Jia
Journal:  Neurosurg Rev       Date:  2016-06-23       Impact factor: 3.042

Review 8.  An overview of meningiomas.

Authors:  Robin A Buerki; Craig M Horbinski; Timothy Kruser; Peleg M Horowitz; Charles David James; Rimas V Lukas
Journal:  Future Oncol       Date:  2018-08-07       Impact factor: 3.404

9.  High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.

Authors:  C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-11-29       Impact factor: 7.038

10.  Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Authors:  Yongli Ji; Cathryn Rankin; Steven Grunberg; Andy E Sherrod; Jamshid Ahmadi; Jeannette J Townsend; Lynn G Feun; Ruth K Fredericks; Christy A Russell; Fairooz F Kabbinavar; Keith J Stelzer; Anne Schott; Claire Verschraegen
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.